血清可溶性白介素2受体水平与急性移植物抗宿主病关系的研究

Objective: To investigate whether the serum levels of sIL-2R were associated with the severity and the therapeutic efficacy of acute graft-versus-host disease. Methods: The therapeutic efficacy of GVHD was determined by the improvement of the symptoms and lab test. The serum levels of sIL-2R were tested with ELISA kit. Results: Serum levels of sIL-2R increased after transplantation and achieved plateau during aGVHD and decreased after regression of aGVHD. Serum levels of sIL-2R were also related to the severity of aGVHD and decreased after complete response following treatment with CD25 monoclonal antibody. On the contrary, in those that didn't response to the treatment, the levels of sIL-2R increased after transient descent. Conclusions: sIL-2R level in serum is related to the severity of aGvHD. CD25 monoclonal antibody can significantly decrease the serum levels of sIL-2R in patients who achieved complete response. These results demonstrate that continuous detection of serum levels of sIL-2R may be helpful to the diagnosis of aGVHD and the evaluation of the therapeutic efficacy of the agent.